A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma

Trial Profile

A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Ragweed allergy immunotherapy (Primary) ; Loratadine; Mometasone; Olopatadine; Salbutamol
  • Indications Rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Acronyms MK-3641-008
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 Jul 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 26 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top